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Abstract
Background: Minor ailments are “self-limiting conditions which may be diagnosed and managed without a medical
intervention”. A cluster randomised controlled trial (cRCT) was designed to evaluate the clinical, humanistic and
economic outcomes of a Minor Ailment Service (MAS) in community pharmacy (CP) compared with usual care (UC).
Methods: The cRCT was conducted for 6 months from December 2017. The pharmacist-patient intervention consisted
of a standardised face-to-face consultation on a web-based program using co-developed protocols, pharmacists’
training, practice change facilitators and patients’ educational material. Patients requesting a non-prescription
medication (direct product request) or presenting minor ailments received MAS or UC and were followed-up by
telephone 10-days after the consultation.
The primary economic outcomes were incremental cost-utility ratio (ICUR) of the service and health related quality of
life (HRQoL). Total costs included health system, CPs and patient direct costs: health professionals’ consultation time,
medication costs, pharmacists’ training costs, investment of the pharmacy and consultation costs within the 10 days
following the initial consultation. The HRQoL was obtained using the EuroQoL 5D-5L at the time of the consultation
and at 10-days follow up. A sensitivity analysis was carried out using bootstrapping. There were two sub-group
analyses undertaken, for symptom presentation and direct product requests, to evaluate possible differences.
Results: A total of 808 patients (323 MAS and 485 UC) were recruited in 27 CPs with 42 pharmacists (20 MAS and 22
UC). 64.7% (n = 523) of patients responded to follow-up after their consultation in CP. MAS patients gained an
additional 0.0003 QALYs (p = 0.053). When considering only MAS patients presenting with symptoms, the ICUR was
24,733€/QALY with a 47.4% probability of cost-effectiveness (willingness to pay of 25,000€/QALY). Although when
considering patients presenting for a direct product request, MAS was the dominant strategy with a 93.69% probability
of cost-effectiveness.
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Conclusions: Expanding community pharmacists’ scope through MAS may benefit health systems. To be fully cost
effective, MAS should not only include consultations arising from symptom presentation but also include an oversight
of self-selected products by patients. MAS increase patient safety through the appropriate use of non-prescription
medication and through the direct referral of patients to GP.
Trial registration: ISRCTN, ISRCTN17235323. Registered 07/05/2021 - Retrospectively registered
Keywords: Community pharmacy services, Primary health care, Self care, Self medication, Nonprescription drugs, Cost-
utility analysis; minor ailment service
Background
The World Health Organization (WHO) defines the
pharmacy practice mission as “contributing to health im-
provement and helping patients with health problems to
make the best use of their medicines” [1]. One of the six
major components of this mission is identifying, man-
aging and triaging health-related problems [1]. Minor
ailments are defined as “common or self-limiting condi-
tions which may be diagnosed and managed without a
medical (i.e. doctor) intervention” [2]. Traditionally, pa-
tients present in community pharmacy (CP) for these
conditions or alternatively self-select a non-prescription
medication [3]. There are many countries where non-
prescription medicines to symptomatically treat these
minor ailments are exclusively available to the public
through CPs [1, 4].
Minor ailment services (MASs) have been imple-
mented in CPs in a number of countries as part of gov-
ernments’ health policies [5–10]. The objective is to
promote CPs as a first point of call for minor ailments,
encouraging patients to seek care at the appropriate level
within the health system [11] thus diminishing cost and
allowing optimal use of health resources. A survey car-
ried out in ten different countries in 2013 [12] stated
that 63% of the population in southern European coun-
tries consulted a general practitioner (GP) when suffer-
ing a minor ailment. Studies have estimated that the
percentage of GP visits due to minor ailments vary be-
tween 18 to 31.2% [13, 14], with 13.2% potentially man-
ageable by CPs [15]. Furthermore, the Australian
Institute of Health and Welfare (AIHW) calculated that
7.5% of the emergency department (ED) visits in
Australia in 2018–2019 were due to non-urgent visits
(triage category 5) [16]. A study carried out in North
East England estimated that up to 8% [15] of ED work-
load is for minor ailment presentations that could poten-
tially be managed in CP.
The economic impact of MAS has been previously
compared to GP and ED settings [15, 17]. Across
England and Scotland, studies have concluded that
MASs release National Health Services (NHS) resources
by redirecting care for minor ailments to lower costs set-
tings such as CP [18, 19] with a total cost annual saving
estimated to be approximately £1.1 billion (2013) [15].
In Canada, a pharmacist prescribing for minor ailment
programs (PPMA) that addressed nine common minor
ailments in the province of Ontario was estimated to
save the health system more than $12.3 million [20].
The Conference Board of Canada calculated a healthcare
cost reduction, by using CP for treating minor ailments
and administering vaccines, between $100 million and
$200 million from avoided GP and ED visits [21]. In an
economic impact analysis in the province of Saskatch-
ewan, PPMA resulted in an estimated health system cost
saving of $546,832 [17].
However, the cost utility or cost effectiveness of MAS
compared to usual care (UC) has been addressed in only
one paper conducted in Australia [22]. The researchers
showed that MAS demonstrated cost effectiveness com-
pared to UC with an incremental cost-utility ratio
(ICUR) of $2277 (95% CI, $681.49–3811.22) (Australian
dollars) per QALY.
The application of MAS to the Spanish health system
requires local data to ensure transferability. Since no
cost utility evaluations have been carried out comparing
MAS to UC in Spain, a study was designed to evaluate
the clinical, humanistic and economic outcomes (ECHO
[23]) of MAS compared with UC in CP. Humanistic and
economic outcomes are reported in this paper.
Methods
Study design
The economic evaluation consisting of a cost utility ana-
lysis (CUA) was undertaken alongside a cluster rando-
mised controlled trial (cRCT). The cRCT was conducted
in Valencia (Spain) for 6 months between December
2017 and May 2018. The full report of the study in
Spanish language is available [24].
Participants
The Pharmaceutical Association of Valencia provided
CPs with study information via phone or email. CPs
within twenty-one municipalities agreed to participate.
The municipalities were the clusters of the study to
avoid contamination between groups. Municipalities
with pharmacies who accepted to participate were
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randomised through a sequence of computer-generated
random numbers to the control (UC) and the MAS arms
applying a ratio of 1:1. Due to the nature of the interven-
tion, pharmacists could not be blinded.
Patients aged ≥16 years or between 2 and 15 years of
age if they were accompanied by a responsible adult,
who were seeking care i.e. presenting symptoms or
requesting a product (direct product request) for the
minor ailments were included in the study. The minor
ailments considered in the study were: dermatological
problems (cold sore, foot fungi), gastrointestinal disturb-
ance (diarrhoea, flatulence, heartburn or vomiting), pain
(dysmenorrhea, headache, sore throat) and upper re-
spiratory tract (cough, cold or nasal congestion).
Description of the intervention (MAS)
The intervention is described using the TIDieR [25]
checklist (Additional file 1). The main components to
the intervention being:
1. A standardised pharmacist–patient consultation
[26] using: co-developed with doctors’ management
protocols for each specific symptom [27], patient
educational material, and a web-based data
collection software [28] that guided pharmacists
through the consultation with selected pop-ups
such as referral criteria (i.e. “red flag symptoms”).
2. Practice change facilitation (PCF): PCFs made
regular on-site visits to MAS CPs to identify and
resolve barriers with service provision and check
the fidelity of the intervention.
3. Educational training for MAS pharmacists was a
twelve-hour training session delivered prior to the
beginning of the trial. It covered service provision,
good practice standards, service protocols,
communication’s skills with the patient and other
health professionals, web-based data collection
software use, data collection and trial protocol.
Patients attending UC pharmacies received usual
pharmacist practice. Normally, in Spain, usual pharma-
cist practice does not include the use protocols or an IT
system. When a patient presents in CP with a minor ail-
ment or requesting a product, a consultation is carried.
However, the depth and breadth of this consultation
does vary. Also, pharmacists in the UC group did not
receive the support of a practice change facilitator.
Pharmacists in the control group attended a three-hour
training on data collection procedures and patient
recruitment.
Study outcomes
Incremental cost-utility ratio (ICUR) of the service and
health related quality of life (HRQoL) were the main
economic and humanistic outcomes. A health system
and patient perspective was chosen.
Data collection was undertaken at the moment of the
consultation in the CP (i.e. patient demographics, medi-
cines supplied, HRQoL) using a web-based data collec-
tion software [28]. Ten days after the consultation,
patients were contacted by telephone by the research
group to collect post consultation data (i.e. HRQOL,
symptom resolution using a Likert scale from 1 “not at
all” to 5 “completely”, reconsultation rates whenever the
patient had to consult again for the same ailment during
the 10 days after prior consultation in CP, type of recon-
sultation which could be CP, GP or emergency depart-
ment). This follow-up time frame was considered
appropriate given minor ailments are self-limiting condi-
tions that should resolve within a short period of time.
Patients self-reported HRQoL using EuroQoL 5D-5L
self-complete version on paper at the time of the phar-
macy consultation and 10 days later through telephone
interview with a researcher using the EuroQoL 5D-5L
telephone version [29].
In addition, the control group documented the con-
sultation, which is not normally part of UC.
Sample size
Sample size calculation was based on the clinical
primary study outcomes. A 10% absolute increase in
appropriate medical referral rate (85 to 95%) [30] and
modification of direct product request (8 to 18%) [31,
32] were estimated. The sample size was calculated with
≥0.9 power, type I error rate of 5%, equal allocation ratio
and assuming an intra-cluster correlation of 0.01. The
larger of the two-estimated sample size calculations was
used to determine the overall sample size, of 726 pa-
tients (allowing for 10% dropout).
Statistical analysis and economic evaluation description
A descriptive analysis was performed to analyse baseline
characteristics by group. Continuous variables were
described using mean and standard deviation (SD) and
categorical variables were presented as counts and per-
centages. Comparison of continuous variables between
groups was undertaken using t-Student test and
Kruskal-Wallis or Mann-Whitney (when skewed). Com-
parison of categorical variables was undertaken using
Pearson’s χ2 tests. The level of statistical significance
was established as p < 0.05.
The research was reported in accordance with the
Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) checklist (Additional file 2) [33].
The effectiveness of the intervention was estimated as
quality-adjusted life years (QALYs). QALYs were
obtained from the cRCT [24] with the HRQoL question-
naire administered at the time of the pharmacy
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consultation using the EuroQoL 5D-5L self-complete
version on paper and at 10-day follow-up via the
telephone interview version by the research team [29].
Utility indexes associated with each health state were
taken from the published Spanish tariff [34]. QALYs
were calculated as area under the curve [35] considering
a 10-day time horizon for patient follow-up. This
method was implemented adding areas under the curve
from geometrical forms obtained by lineal interpolation
between utility values during the study period (10 days).
Due to missing data in the sample in relation to the EQ-
5D-5L data at follow-up, multiple imputation with
chained equations was performed in order to allocate
data. The multiple imputation missing data model in-
cluded as predictive variables, EQ-5D-5L indices, at
baseline and follow-up, and patient characteristics such
as sex, age, and type of minor ailment (dermatological
problems, gastrointestinal disturbance, pain and upper
respiratory tract).
Firstly, the missing data were imputed under the miss-
ing at random (MAR) assumption; this was the main
analysis (base-case scenario). Secondly, a completed case
analysis was performed, assuming that patients who
completed all follow-up were representative of the entire
sample who initially agreed to participate. In this case,
all participants who did not return the HRQoL question-
naire were removed, which assumes data is missing
completely at random (MCAR). A simple pattern mix-
ture model was implemented, following the approach
recommended by Faria et al. [36] The utilities shown in
both cases have been adjusted for age, gender, type of
minor ailment, symptom duration and baseline utility.
Total direct costs included costs to the health system,
CPs and direct patient costs. Direct costs included the
cost of health professionals’ consultation time, medica-
tion costs, pharmacists’ training costs and investment of
the pharmacy (infrastructure, etc.) and costs of patients’
re-consultation in the following 10 days after initial con-
sultation in CP (including contacts with all health pro-
viders such as GP and ED consultations). To value each
resource item in terms of its unit cost, additional data
was used:
– Medication costs, as out-of-pocket costs borne by
the patient, were based on official prices listed in the
Bot Plus® database at September 2018 [37].
– CP consultation costs (for both groups) were
calculated on time spent by pharmacists for the
provision of the service, obtained from the
pharmacists’ web-based data collection software for
the cRCT. Considering pharmacist role (supervisor/
regular pharmacist): time used for pharmacist-
patient consultation was 8.00 min (SD = 2.45) for a
supervisor in MAS group, 5.35 min (SD = 3.20) for a
regular pharmacist in MAS group, 6.57 min (SD =
3.90) for a supervisor in UC group and 4.95 min
(SD = 3.85) for a regular pharmacist in UC group.
Pharmacists in UC group were asked to document
the consultation which is not part of usual care.
– The unit cost of labour of the community
pharmacist was calculated using the pharmacist’
salary as determined by the Spanish community
pharmacy agreement [38]. Supervisor pharmacists’
salary was 0.315 €/minute and regular pharmacists’
salary was 0.293 €/minute.
– To calculate the costs related to the infrastructure
investment and maintenance costs for the
pharmacy, estimates were used from a previous
Spanish study [39].
– Pharmacist training costs were for the twelve-hour
course (classroom costs, presenter’s costs, travels
and accommodation costs).
– GP (56.95€) and ED (105.27€) consultation costs
were based on Valencian Law 20/2017 [40].In order
to allocate the costs proportional to each patient,
the mean cost of investment per pharmacy was
divided by the mean estimated number of patients
included in a potential MAS per CP. A study
conducted by the General Pharmaceutical Council
of Spain stated that 15–20% of patients attending
community pharmacy presented with minor ailment
symptoms or were self-selecting a medication for
treatment of their symptoms [41]. Five thousand
four hundred patients were estimated to potentially
access a CP MAS annually with an estimated of
approximately 120 patients per day per CP [42].
The investment of pharmacies in the UC group was
assumed to be null.
Seemingly unrelated regression (SUR) was used to
jointly model costs and QALYs.Cost and QALY were
adjusted for sex, age, type of minor ailment, and QALYs
were also adjusted for baseline utility to account for dif-
ferences between groups at baseline. Coefficients were
combined across the multiple imputed datasets using
Rubin’s rules [36].
To assess the robustness of the results, a subgroup
analysis and probability analysis was carried out along-
side the missing data model described above. The two
subgroups analysis accounting for presentation type
were performed to evaluate possible differences. This in-
cluded patients presenting to the CP with symptoms or
patients directly requesting a product.
The probabilistic analysis assesses the uncertainty in
cost and outcomes across both alternatives of the study
(MAS and UC) and was conducted by bootstrapping
cost and QALY pairs from each patient with 1000 repli-
cates. The results of the replicates are presented in the
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cost-utility plane. The probability of the intervention
being cost-effective was calculated assuming data was
bivariate and normally distributed [43].
In addition, a cost-effectiveness acceptability curve
(CEAC) was derived to estimate the probability of the
intervention being cost-effective at different amounts of
society’s willingness to pay for health outcomes. Since
there is not a formal QALY monetary value assigned by
the Valencian or National Spanish government, a study
carried out by the government in Canary Island (Spain)
[44] was used for the assignment of a monetary value to
the QALY. They suggested a willingness to pay per
QALY from €20,000 to €25,000. All analyses were per-
formed using STATA 14 [45].
Ethics approval and consent to participate
The study was approved by the University of Granada
Ethics Committee (approval number 331/CEIH/2017)
and Xátiva-Ontinyent Ethics Committee “Lluís Alcanyís”.
All methods were carried out in accordance with relevant
guidelines and regulations. Pharmacists were informed of
the study and provided written consent to participate. In-
formed consent was obtained from all subjects and/or
their legal guardian(s).
Trial registration




A total of 808 patients (13 MAS and 14 UC) were re-
cruited in 27 CPs with 42 pharmacists (20 MAS and 22
UC) (characteristics are included in Additional file 3).
Most patients were female (63.1%, n = 510), presented
with upper respiratory tract symptoms (65.5%, n = 529),
had a symptom presentation (69.8%, n = 564), presented
symptoms suffered previously (91.6%, n = 740) and had
not treated their symptoms for this episode prior to vis-
iting the pharmacy (78.8%, n = 637). The mean patient
age was 47.6 years old (SD = 16.6). Statistical differences
between groups were only found for baseline HRQoL
(both utility and EQ-VAS); the MAS group presented a
utility index of 0.87 (SD = 0.12) compared to the UC
group, of 0.89 (SD = 0.14) (p < 0.001). Patients visiting
MAS pharmacies with direct product requests had lower
baseline HRQoL (0.86, SD = 0.11) compared with UC
patients (0.90, SD = 0.12) (p = 0.020).
Health system, CPs and patient direct costs are pre-
sented in Table 1. Thirty pharmacists attended each
training sessions and thus the cost per pharmacist was
272.20€ (overall training cost was 3090€/30 pharma-
cists), with pharmacist’s time costing 169.20€. Approxi-
mately 5400 patients were estimated to potentially
access a CP MAS annually per pharmacy [39] with a
training cost per consultation of 0.05€. Training costs
were only included for the MAS pharmacies.
The total infrastructure investment and maintenance
costs were estimated to be €2883.43 per year with a cost
per consultation of 0.53€.
A total of 523 patients were followed up after consult-
ation in CP (64.7% out of the 808 patients), 292 in UC
pharmacies and 231 in MAS group (Fig. 1). The number
of patients lost to follow-up was a total of 35.3% (n =
285). Within the MAS group this lost was 28.5% (92/
323) compared to the UC group of 39.8% (193/485).
HRQoL was higher for those patients visiting MAS CPs
with no statistically significant differences found between
groups at follow-up (p = 0.053 without multiple imput-
ation and p = 0.042 with multiple imputation) (Table 2).
Table 1 Summary of identified health resources and cost estimates
MAS CPa (n = 323)
Mean (SDb) (€)
UC CPa (n = 485)
Mean (SDb) (€)
P-value
Medication costc 7.67 (2.62) 7.88 (3.11) 0.331
Consultation costd 1.55 (0.95) 1.13 (1,05) 0.000
Training cost 0.05 (0.00) 0.00 (0.00) NA
Infrastructure and maintenance cost 0.53 (0.00) 0.53 (0.00) NA
Total cost consultation in CP 9.80 (3.37) 9.54 (4.07) 0.012
Cost of other visits to GP or ED 11.61 (13.19) 4.94 (9.35) 0.001
Total coste 21.41 (30.39) 14.48 (23.38) 0.001
aUC CP Usual Care Community Pharmacy, MAS CP Minor Ailment Service Community Pharmacy
bSD: Standard Deviation
cIn Spain, medication costs are paid by the patient
dConsidering pharmacist role (supervisor/regular pharmacist): time used for pharmacist-patient consultation was 8.00 min (SD = 2.45) for a supervisor in MAS
group, 5.35 min (SD = 3.20) for a regular pharmacist in MAS group, 6.57 min (SD = 3.90) for a supervisor in UC group and 4.95 min (SD = 3.85) for a regular
pharmacist in UC group. Pharmacists in UC group were asked to document the consultation which is not part of usual care
eFirst consultation in CP and other consultations during the 10 days studied were considered
NA Not applicable
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Fig. 1 CONSORT 2010 Flowchart: Minor Ailment Service and usual pharmacist care
Table 2 EuroQoL 5D-5L scores (adjusted)




Number with missing data
at 10 days




UC CPa (n =
285)
0 0.911 (0,010) 200 0.921 (0.011)
MAS CPa
(n = 224)
2 0.891 (0,011) 101 0.922 (0.013)
P value 0.170 0.053
With multiple imputation
(base case)
UC CPa (n =
285)
0 0.900 (0.008) 0 0.917 (0.018)
MAS CPa
(n = 222)
0 0.881 (0.009) 0 0.926 (0.014)
P value 0 0.051 0 0.042
aUC CP Usual Care Community Pharmacy, MAS CP Minor Ailment Service Community Pharmacy
bSD: Standard Deviation
cAdjusted by patient’s age and gender, minor ailment and symptom duration and baseline utility
Amador-Fernández et al. BMC Health Services Research         (2021) 21:1253 Page 6 of 14
When considering multiple imputation (base case ana-
lysis), the incremental cost-utility (ICUR) of MAS was
19,325€ per QALY with a 66.45% probability of cost-
utility using a willingness to pay of 25,000€/QALY
(Table 3). The results in the complete case scenario
(without multiple imputation) had a slightly higher
ICUR of 24,733€ per QALY.
Thirty percent (n = 244) of patients self-selected a prod-
uct to treat their minor ailment (Additional file 3). When
cost-utility was studied for these patients, MAS was the
dominant strategy with a 97.32% probability of cost-utility
with a willingness to pay of 25,000€/QALY (Table 3).
Over one-third of the bootstrap simulations were lo-
cated in the upper-right quadrant (53.29%) of the cost-
utility plane with a willingness to pay of 20,000€/QALY
(Fig. 2).Differences were found when only considering
symptom presentation (Fig. 3) compared to direct prod-
uct request presentation types (Fig. 4). When only con-
sidering direct product request, most of the bootstrap
simulations were located under the threshold for a will-
ingness to pay of 20,000€/QALY (96.83%) (Fig. 4).
The acceptability curve shows that if the willingness to
pay is 25,000€/QALY, the probability of MAS being cost
effective, compared with UC, is 66.45% (Fig. 5). It de-
creases when considering symptom presentation (Fig. 6)
and increases to 97.32% for consultations due to direct
product requests (Fig. 7).
Discussion
This is the first study to evaluate cost utility for a MAS
in Spanish CPs compared to UC. The results of the
study showed that implementing MAS has clinical bene-
fits for patients, resulting in higher HRQoL as shown in
previous studies [19, 22]. A positive effect was obtained
in HRQoL when a ten-day time horizon was contem-
plated. Although, when MAS includes both, symptom
presentation and direct product request, there is a low
probability that MAS is cost-effective compared to UC.
Minor ailments are self-limiting, they may have an im-
pact in patients’ daily life so patients’ perception of their
health status can change in a relative short period. In
addition, MAS allows the provision of additional










Probability of cost effectiveness
WTP 20,000€ WTP 25,000€ WTP 30.000
All sample
Multiple imputation (base case)
UC CPa 10.68 0.0246
MAS CPa 17.19 6.51 0.0247 0.0003 19,325 52.39% 66.45% 75.36%
Complete Cases
UC CPa 12.61 0.0245
MAS CPa 20.03 7.42 0.0248 0.0003 24,733 36.19% 47.40% 60.10%
Subgroup with symptom presentation
Multiple imputation (base case for subgroup analysis)
UC CPa 10.35 0.0245
MAS CP* 19.48 9.13 0.0247 0.0002 42,322 14.09% 23.92% 33.15%
Complete Cases
UC CPa 12.59 0.0245
MAS CPa 22.97 10.45 0.0248 0.0002 48,126 11.20% 17.39% 24.40%
Subgroup with direct product request
Multiple imputation (base case for subgroup analysis)
UC CPa 11.59 0.0242
MAS CPa 11.90 0.31 0.0248 0.0006 523 96.83% 97.32% 97.58%
Complete Cases
UC CP* 14.25 0.0247
MAS CPa 13.54 −0.71 0.0249 0.0006 Dominant 92.60% 93.69% 94.49%
aUC CP Usual Care Community Pharmacy, MAS CP Minor Ailment Service Community Pharmacy
bAdjusted by patient’s age and gender, minor ailment, symptom duration and QALY at baseline (first consultation in CP and other consultations such as GP or ED
visits during the 10 days studied were considered)
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information about conditions or medicines, and referral
to other health care professionals when needed.
When studying consultation costs, medication expen-
sesaccounted for the main costs of the consultation. In
Spain, the total costs of the medication bought without a
prescription (over-the-counter medication) is paid by
the patient. The cost of the medication was 80% of the
total consultation cost.
Medication costs were similar in both groups. Pharma-
cists in the MAS group spent longer with the patient as
would be expected due to the depth of the consultation.
Total consultation costs (considering the first consultation
Fig. 2 Bootstrap for both (symptom presentation and direct product request) and willingness to pay of 20,000€ (base case)
Fig. 3 Bootstrap for symptom presentation and willingness to pay of 20,000€
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in CP and any additional consultations within 10 days)
was higher in the MAS group due to greater number of
direct referrals to other health professionals. Some of the
referral criteria used to refer patients in the agreed proto-
cols were for example for “patients over 75 years old who
had underling chronic conditions when suffering upper
respiratory tract symptoms, long duration of symptoms (7
days without previous treatment or 72 h if treated without
recovery) or high temperature (38 °C). Increasing appro-
priate referral may improve patient’s safety.
Fig. 4 Bootstrap for direct product request and willingness to pay of 20,000€
Fig. 5 Acceptability curve MAS-UC (complete cases and multiple imputation)
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Fig. 6 Acceptability curve MAS-UC (complete cases and multiple imputation for symptom presentation)
Fig. 7 Acceptability curve MAS-UC (complete cases and multiple imputation for direct product request)
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The results showed an ICUR of 19,325€/QALY due to
the increase in QALY gain during 10 days after the con-
sultation in MAS CPs compared to the UC group. These
results are higher than obtained internationaly [22]
(AUD $2277/ QALY) and may be due follow-up occur-
ring at 10 days in this study, and at 14-days in the Aus-
tralian study. Since the QALYs were estimated over a
10-day period, the gains for MAS CP group could have
extended beyond the 10-day period.
Different studies [11, 15–17] have proven that when a
MAS is implemented, it reduces GP consultations and de-
crease the number of patients presenting minor ailment
symptoms at primary health care centres due to the shift
of consultations between settings. Our study results
showed that it is important to extend this service to direct
product requests since the evidence suggests that there is
increase in HRQoL, cost effectiveness and patient safety.
MAS pharmacists modified by 11.4% [24] (compared to
4.5% in UC CP) the medication requested by the patients.
Using the willingness to pay threshold of 25,000€, MAS
was the dominant strategy with a 97.32% probability of
cost-utility for patients with direct product requests.
As shown in previous studies, consultations were per-
formed differently when symptoms were presented than
for a direct product request [46]. When a patient pre-
sents with symptoms and is directly asking for advice, it
provides an easier opportunity for the pharmacist to
conduct a deeper consultation. The self-selection of the
product by patient makes it challenging for pharmacists
to intervene and in usual practice less advice is report-
edly given to those patients [47, 48]. It appears that CPs
are more engaged when resolving symptom presenta-
tions than when dealing with product requests [47, 48].
As this study showed, using protocols to deal with direct
product requests has a greater effect on HRQoL, and
therefore, MAS is more likely to be cost-effective than
when only considering symptom presentations. Imple-
menting quality standards in CP helps promote the safe
and effective management of minor ailments [1, 49] and
appropriate self-selection of non-prescription medica-
tions. MAS also limited the variability in community
pharmacy consultations through training and the use of
a standard process.
While this study only focussed on MAS versus UC,
comparing MAS versus GP and ED visits in Spain would
be valuable. The international literature suggests that
implementing MAS may reduce the burden in GP and ED
visits decreasing primary health spending [15, 17–19, 22].
In Spain, it has been suggested that CPs could help reduce
primary care pressure through managing minor ailments
[50]. In Spain in 2018, 230.6 million GP consultation and
28.7 million ED consultations took place [51]. Health ex-
penditure in 2018 was 71,145 million € with only 14.6%
(10,387 million €) intended to primary health care [52]. A
Spanish national study carried out in 2018 concluded that
86.8% of the population visited the GP during the 12
months before and 15.4% over 15 years old could not get
an appointment with their GP on time [53]. In Spain, GP
consultations increased by 17% and by 18% for ED presen-
tations between 1987 and 2017 [54]. Therefore, the imple-
mentation of MAS may lead to a more efficient use of the
primary health care resources.
Methodological limitations
There are a number of methodological limitations for
this study:
The study took place in the province of Valencia, lim-
iting the generalizability of results to a national level.
The number of patients lost to follow-up was 35.3% (n =
285), it is interesting to note that a greater percentage of
MAS patients responded to follow-up 10 days after the
consultation, compared to the UC group. This may be
due to the increased time spent with the patient during
the MAS consultation.
Due to the impossibility of following patients up daily,
the period established to contact patients after consulting
the CP was 10 days, in some cases, the minor ailments did
not fully resolve within the 10-days period (39.6%) and re-
covered before 10 days (60.4%). This could represent a
limitation to our study as we took, for practical reasons, a
10-days period for the second measurement of the QALY.
Data obtained for consultations to GP and ED that took
place during the 10 days after the initial consultation in
CP were self-reported by the patient and not validated
with official data. Future studies should contemplate the
use of health system data to obtain a more reliable health
system cost and should consider the inclusion of product-
ivity costs and costs of any prescribed medications in sub-
sequent consultations. PCFs costs were not included due
to the limited time spent with community pharmacists
and lack of reliable documentation.
The UC group was asked to document the consult-
ation. Therefore, consultation time and consultation
costs in the UC group may be overestimated.
Conclusion
This is the first Spanish study to evaluate the economic
impact of a MAS in CP, obtaining similar results to
those carried out internationally. The overall findings
showed that there is significant potential to adopt a
MAS in Spain with an addition of including direct prod-
uct request so that it has a higher impact on the health
system. MAS may add further economic benefits due to
the appropriateness of self-medication with non-
prescription medicines. Expanding community pharma-
cists’ scope through MAS may benefit health systems;
therefore, the contribution by CPs to this aspect of pri-
mary health care should not be underestimated.
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